Clinical Trial Update: Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a condensed regimen (mini-Hyper-CVD with rituximab, inotuzumab ozogamicin, and blinatumomab) for relapsed pediatric B-cell acute lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• Besponsa (inotuzumab ozogamicin)
• Rituxan (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: RECRUITING